A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

NCT00085826 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Exisulind

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]